Editorial: Immunotherapy in Multiple Myeloma.
作者信息
Giuliani Nicola, Malavasi Fabio
机构信息
Department of Medicine and Surgery, University of Parma, Parma, Italy.
U.O. di Ematologia e Centro Trapianti Midollo Osseo, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy.
出版信息
Front Immunol. 2019 Aug 14;10:1945. doi: 10.3389/fimmu.2019.01945. eCollection 2019.
Abstract
摘要
相似文献
1
Editorial: Immunotherapy in Multiple Myeloma.社论：多发性骨髓瘤的免疫疗法
Front Immunol. 2019 Aug 14;10:1945. doi: 10.3389/fimmu.2019.01945. eCollection 2019.
2
Anti-CD38 and anti-SLAMF7: the future of myeloma immunotherapy.抗CD38和抗信号淋巴细胞激活分子家族成员7：骨髓瘤免疫治疗的未来
Expert Rev Hematol. 2018 May;11(5):423-435. doi: 10.1080/17474086.2018.1456331. Epub 2018 Mar 27.
3
Comparison of monoclonal antibodies targeting CD38, SLAMF7 and PD-1/PD-L1 in combination with Bortezomib/Immunomodulators plus dexamethasone/prednisone for the treatment of multiple myeloma: an indirect-comparison Meta-analysis of randomised controlled trials.比较针对 CD38、SLAMF7 和 PD-1/PD-L1 的单克隆抗体联合硼替佐米/免疫调节剂与硼替佐米/免疫调节剂联合地塞米松/泼尼松治疗多发性骨髓瘤的疗效：一项随机对照试验的间接比较荟萃分析。
BMC Cancer. 2021 Sep 6;21(1):994. doi: 10.1186/s12885-021-08588-9.
4
Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.靶向多发性骨髓瘤中的 B 细胞成熟抗原（BCMA）：基于 BCMA 的免疫疗法的潜在用途。
Front Immunol. 2018 Aug 10;9:1821. doi: 10.3389/fimmu.2018.01821. eCollection 2018.
5
Combinatorial targeting of multiple myeloma by complementing T cell engaging antibody fragments.通过互补 T 细胞结合抗体片段对多发性骨髓瘤进行组合靶向治疗。
Commun Biol. 2021 Jan 8;4(1):44. doi: 10.1038/s42003-020-01558-0.
6
Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma.针对多发性骨髓瘤的 CD38 和 SLAMF7 单克隆抗体的临床疗效和管理。
Blood. 2016 Feb 11;127(6):681-95. doi: 10.1182/blood-2015-10-646810. Epub 2015 Dec 2.
7
Coexistence of leishmaniasis and multiple myeloma in the era of monoclonal antibody (anti-CD38 or anti-SLAMF7) containing triplets: one shared story of two exceptional cases.在含单克隆抗体（抗CD38或抗信号淋巴细胞激活分子家族成员7）的三联疗法时代利什曼病与多发性骨髓瘤的共存：两例特殊病例的共同故事
Leuk Lymphoma. 2018 Apr;59(4):983-987. doi: 10.1080/10428194.2017.1361031. Epub 2017 Aug 7.
8
CD38-Targeted Immunochemotherapy in Refractory Multiple Myeloma: A New Horizon.CD38 靶向免疫化疗治疗难治性多发性骨髓瘤：新的曙光。
Clin Cancer Res. 2015 Jun 15;21(12):2660-2. doi: 10.1158/1078-0432.CCR-14-3190. Epub 2015 Apr 15.
9
Three new drugs for multiple myeloma.三种用于治疗多发性骨髓瘤的新药。
Med Lett Drugs Ther. 2016 May 23;58(1495):e70-1.
10
[Bispecific antibodies in multiple myeloma].[多发性骨髓瘤中的双特异性抗体]
Bull Cancer. 2021 Oct;108(10S):S205-S212. doi: 10.1016/j.bulcan.2021.10.003.
引用本文的文献
1
The Circular Life of Human CD38: From Basic Science to Clinics and Back.人类 CD38 的循环生命：从基础科学到临床再到基础科学。
Molecules. 2020 Oct 21;25(20):4844. doi: 10.3390/molecules25204844.
2
CD38 and Anti-CD38 Monoclonal Antibodies in AL Amyloidosis: Targeting Plasma Cells and beyond.CD38 与抗 CD38 单克隆抗体在 AL 淀粉样变性中的应用：靶向浆细胞及其他方面。
Int J Mol Sci. 2020 Jun 10;21(11):4129. doi: 10.3390/ijms21114129.
3
ImmunoPET in Multiple Myeloma-What? So What? Now What?多发性骨髓瘤中的免疫正电子发射断层扫描——是什么？那又怎样？现在该怎么办？
Cancers (Basel). 2020 Jun 4;12(6):1467. doi: 10.3390/cancers12061467.
4
Therapeutic Monoclonal Antibodies and Antibody Products: Current Practices and Development in Multiple Myeloma.治疗性单克隆抗体及抗体产品：多发性骨髓瘤的当前实践与发展
Cancers (Basel). 2019 Dec 19;12(1):15. doi: 10.3390/cancers12010015.
本文引用的文献
1
Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy.肿瘤靶向 4-1BB 激动剂与 T 细胞双特异性抗体联合作为现货治疗。
Sci Transl Med. 2019 Jun 12;11(496). doi: 10.1126/scitranslmed.aav5989.
2
Twists and turns to translating 4-1BB cancer immunotherapy.4-1BB 癌症免疫疗法的曲折历程。
Sci Transl Med. 2019 Jun 12;11(496). doi: 10.1126/scitranslmed.aax4738.
3
Multifunctional Natural Killer Cell Engagers Targeting NKp46 Trigger Protective Tumor Immunity.多功能自然杀伤细胞衔接器靶向 NKp46 触发保护性肿瘤免疫。
Cell. 2019 Jun 13;177(7):1701-1713.e16. doi: 10.1016/j.cell.2019.04.041. Epub 2019 May 30.
4
Daratumumab in combination with urelumab to potentiate anti-myeloma activity in lymphocyte-deficient mice reconstituted with human NK cells.达雷妥尤单抗联合urelumab增强用人自然杀伤细胞重建的淋巴细胞缺陷小鼠的抗骨髓瘤活性。
Oncoimmunology. 2019 Apr 13;8(7):1599636. doi: 10.1080/2162402X.2019.1599636. eCollection 2019.
5
Mechanism of Action of a New Anti-CD38 Antibody: Enhancing Myeloma Immunotherapy.新型抗 CD38 抗体的作用机制：增强骨髓瘤免疫疗法。
Clin Cancer Res. 2019 May 15;25(10):2946-2948. doi: 10.1158/1078-0432.CCR-19-0260. Epub 2019 Mar 7.
6
Immunotherapy in myeloma: how far have we come?骨髓瘤的免疫疗法：我们已经取得了多大进展？
Ther Adv Hematol. 2019 Jan 18;10:2040620718822660. doi: 10.1177/2040620718822660. eCollection 2019.
7
Novel Agents in Multiple Myeloma.多发性骨髓瘤的新型药物。
Cancer J. 2019 Jan/Feb;25(1):45-53. doi: 10.1097/PPO.0000000000000355.
8
The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma.抗 CD38 单克隆抗体伊沙妥昔单抗在多发性骨髓瘤中的作用机制。
Clin Cancer Res. 2019 May 15;25(10):3176-3187. doi: 10.1158/1078-0432.CCR-18-1597. Epub 2019 Jan 28.
9
Current use of monoclonal antibodies in the treatment of multiple myeloma.目前在多发性骨髓瘤治疗中使用的单克隆抗体。
Br J Haematol. 2018 May;181(4):447-459. doi: 10.1111/bjh.15121. Epub 2018 Apr 25.
10
CD38 antibodies in multiple myeloma: back to the future.多发性骨髓瘤中的 CD38 抗体：回到未来。
Blood. 2018 Jan 4;131(1):13-29. doi: 10.1182/blood-2017-06-740944. Epub 2017 Nov 8.
Zotero 插件